Background: To evaluate the effectiveness of hyaluronic acid (HA) gel injection with and without plasma rich in growth factors (PRGF) for the management of interdental papillary loss. Methods: A single blinded randomized clinical trial was carried out on 21 subjects with 34 sites. Patients within the age group 18–45 years who had Class I and II papillary recession in the maxillary anterior region were selected. The sites involved were randomly assigned to Group HA alone and Group HA + PRGF. The patients were recalled 4 weeks after receiving supragingival and subgingival instrumentation. HA or HA + PRGF was injected into the defective papilla at baseline and at 3 and 6 weeks. Image based measurements of Papillary Width (PW), Papillary Deficient Height (PDH), Deficient Area (DA), Deficient Volume (DV) were registered at baseline, 3 weeks, 6 weeks and 12 weeks. A vernier caliper was used to measure the papillary depth in the impression made using additional silicone impression material pre- and post-intervention. Results: There was a significant improvement in the within-group comparison of PW, PDH, DA and DV in both the groups. Group HA + PRGF showed significantly greater improvement in comparison to Group HA alone in terms of PDH, DA and DV at 6 and 12 weeks. Conclusions: Even though HA gel has already been established as a promising injectable agent in the minimally invasive treatment of interdental papillary deficiency, PRGF may also have a significant adjuvant effect when used along with HA. Further clinical studies with longer follow up duration, larger sample size and standardization of the tooth shape are required for a better understanding of the adjuvant effect of PRGF when used along with HA.

No abstract

Jacob’s disease is a rare entity consisting of the formation of a pseudojoint between an abnormal coronoid process of the mandible and the inner surface of the zygomatic bone. First described by Jacob in 1899, its diagnosis and definition have never been entirely univocal. In this paper, we present three emblematic cases and an extensive review of the literature on Jacob’s disease. Given the variability observed in the presentation of the disease, we have developed a proposal for the classification, here reported.

This comparative study included 146 patients that are under risk of developing MRONJ and needed oral rehabilitation with implant-supported prosthesis. All the included patients had metabolic profile assessments and were divided into two groups: G1-normal osteometabolic profile (92 patients), G2- altered osteometabolic profile (54 patients). All patients in G1, regardless of gender and type of prosthetic rehabilitation, showed a regular osseointegration process without any complications. However, 42 patients in G2 (77%) were diagnosed with MRONJ within six months afterimplant insertions, which did not compromise implant osseointegration and prosthetic rehabilitation. In other 12 patients (23%) in adjunct to ONJ development, implants did not osseointegrate. All patients with ONJ were successfully treated according to the SISBO pharmacological protocol.According to the results of this study, osteometabolic profile assessment can be considered a useful tool in terms of decreasing the risk of developing ONJ in patients.